Waiver request of in-vivo testing: 20 mg/1.1 gm based on (i) acceptable bioequivalence studies on the 40 mg/1.1 gm strength, (ii) acceptable dissolution testing across all strengths, and (iii) proportional similarity in the formulations across all strengths.